Asset
PEVIFOSCORVIR SODIUM
ALIGOS THERAPEUTICS INC. COMMON STOCK
Revenue
No revenue reported in loaded filings.
Clinical trials (5)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06672900 | phase1 | active_not_recruiting | 2025-01-09 | 2025-07-07 | Aligos Therapeutics | A Multi-part Study of ALG-000184 to Evaluate Safety, Tolerability, Pharmacokinetics and Drug-drug Interaction Potential After Single and Multiple Doses in Healthy Volunteers |
| NCT06963710 | phase2 | active_not_recruiting | 2025-07-15 | 2027-03-01 | Aligos Therapeutics | A Study Evaluating the Efficacy and Safety of ALG-000184 Compared With Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg- Negative Adult Subjects With Chronic Hepatitis B (B-SUPREME) |
| NCT04536337 | phase1 | completed | 2020-10-22 | 2025-06-16 | Aligos Therapeutics | A Study of ALG-000184 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single and Multiple Doses in Healthy Volunteers and CHB Subjects |
| NCT07342881 | phase1 | completed | 2026-03-10 | 2026-07-29 | Aligos Therapeutics | Single Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Participants With Renal Impairment and in Healthy Participants With Normal Renal Function |
| NCT07342868 | phase1 | completed | 2026-01-30 | 2026-08-19 | Aligos Therapeutics | Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Subjects With Moderate Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function |
FDA applications (0)
This company has no applications containing this asset.